Editorial: Small cell lung cancer: New drugs and strategies

Editorial: Small cell lung cancer: New drugs and strategies

Bibliographic Details
Main Authors:	Diego L. Cortinovis, Alessandro Morabito
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-01-01
Series:	Frontiers in Medicine
Subjects:	SCLC immunotherapy lurbinectedin anti-DLL3 drugs Aurora kinase inhibitors
Online Access:	https://www.frontiersin.org/articles/10.3389/fmed.2023.1140642/full

Similar Items

Unlocking New Horizons in Small-Cell Lung Cancer Treatment: The Onset of Antibody–Drug Conjugates
by: Lorenzo Belluomini, et al.
Published: (2023-11-01)

Targeting the Notch signaling pathway and the Notch ligand, DLL3, in small cell lung cancer
by: Huan Zhang, et al.
Published: (2023-03-01)

Novel Cytotoxic Chemotherapies in Small Cell Lung Carcinoma
by: Diego Cortinovis, et al.
Published: (2021-03-01)

Expression patterns and clinical implications of PDL1 and DLL3 biomarkers in small cell lung cancer retrospectively studied: Insights for therapeutic strategies and survival prediction
by: Kalliopi Domvri, et al.
Published: (2024-03-01)

Design of two immunotoxins based rovalpituzumab antibody against DLL3 receptor; a promising potential opportunity
by: Mohammad Hossein Ataee, et al.
Published: (2022-01-01)

A model-based head-to-head comparison of single-agent lurbinectedin in the pivotal ATLANTIS Study
by: Salvador Fudio, et al.
Published: (2023-06-01)

ASCL1 and DLL3 expressions and their clinicopathological implications in surgically resected pure small cell lung cancer: A study of 247 cases from the National Cancer Center of China
by: Chunfang Hu, et al.
Published: (2022-02-01)

Small-Cell Lung Cancer—An Update on Targeted and Immunotherapies
by: Nicholas McNamee, et al.
Published: (2023-05-01)

Advances in new targets for immunotherapy of small cell lung cancer
by: Zitong Zheng, et al.
Published: (2024-01-01)

Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization
by: Rebekah Rittberg, et al.
Published: (2022-12-01)

New therapies in small cell lung cancer: A narrative review
by: Sotirios Papavasileiou, et al.
Published: (2024-03-01)

Editorial: Updates on combination therapy for lung cancer volume II
by: Alberto Pavan, et al.
Published: (2024-04-01)

Safety evaluation of immune checkpoint inhibitors combined with chemotherapy for the treatment of small cell lung cancer: A meta‐analysis of randomized controlled trials
by: Vito Longo, et al.
Published: (2023-04-01)

Aurora B Inhibitors as Cancer Therapeutics
by: Antal H. Kovacs, et al.
Published: (2023-04-01)

Pan Aurora Kinase Inhibitor: A Promising Targeted-Therapy in Dedifferentiated Liposarcomas With Differential Efficiency Depending on Sarcoma Molecular Profile
by: Jean Camille Mattei, et al.
Published: (2020-03-01)

Aurora kinase inhibitors: which role in the treatment of chronic myelogenous leukemia patients resistant to imatinib?
by: Giovanni Martinelli, et al.
Published: (2009-02-01)

Chemo-Immunotherapy in First Line Extensive Stage Small Cell Lung Cancer (ES-SCLC): A Systematic Review and Meta-Analysis
by: Arani Sathiyapalan, et al.
Published: (2022-11-01)

When Just One Phosphate Is One Too Many: The Multifaceted Interplay between Myc and Kinases
by: Dalila Boi, et al.
Published: (2023-03-01)

Unweaving the mitotic spindle: A focus on Aurora kinase inhibitors in lung cancer
by: Alessio Stefani, et al.
Published: (2022-10-01)

Phase II study of durvalumab (MEDI 4736) plus carboplatin and etoposide in elderly patients with extensive stage small cell lung cancer: Study protocol of turtle study (LOGIK 2003)
by: Hidenobu Ishii, et al.
Published: (2023-01-01)

Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug–Drug Interaction Study
by: Irene Moreno, et al.
Published: (2024-01-01)

ATR inhibition augments the efficacy of lurbinectedin in small‐cell lung cancer
by: Christopher W Schultz, et al.
Published: (2023-08-01)

Extensive Stage Small-Cell Lung Cancer with Cystic Brain Metastases: A Report of Two Cases
by: Cai F, et al.
Published: (2024-03-01)

An Aurora kinase inhibitor, AMG900, inhibits glioblastoma cell proliferation by disrupting mitotic progression
by: Jaewook Ryu, et al.
Published: (2018-11-01)

Immunotherapy for extensive-stage small-cell lung cancer: current landscape and future perspectives
by: Shuang Zhang, et al.
Published: (2023-04-01)

Small Cell Lung Cancer: Emerging Targets and Strategies for Precision Therapy
by: Shruti R. Patel, et al.
Published: (2023-08-01)

Pathology and Classification of SCLC
by: Maria Gabriela Raso, et al.
Published: (2021-02-01)

7-(2-Anilinopyrimidin-4-yl)-1-benzazepin-2-ones Designed by a “Cut and Glue” Strategy Are Dual Aurora A/VEGF-R Kinase Inhibitors
by: Mehmet Karatas, et al.
Published: (2021-03-01)

Treating patients with platinum-sensitive extensive-stage small-cell lung cancer in a real-world setting
by: Jacob Sands, et al.
Published: (2023-12-01)

Rationale and design of a multicenter, randomized phase II trial of durvalumab with or without multitarget tyrosine kinase inhibitor as maintenance treatment in extensive‐stage small‐cell lung cancer patients (DURABLE study)
by: Bo Zhang, et al.
Published: (2023-12-01)

In Vitro High Throughput Screening, What Next? Lessons from the Screening for Aurora Kinase Inhibitors
by: Thi-My-Nhung Hoang, et al.
Published: (2014-02-01)

Inhibitors of One or More Cellular Aurora Kinases Impair the Replication of Herpes Simplex Virus 1 and Other DNA and RNA Viruses with Diverse Genomes and Life Cycles
by: Cindy Y. Ly, et al.
Published: (2023-02-01)

Radiotherapy and Immunotherapy in Lung Cancer
by: Kristin Hsieh, et al.
Published: (2023-06-01)

Editorial: Trabectedin, lurbinectedin, and other marine-derived anticancer alkaloids on solid cancer: Mechanisms of action, clinical impact, and future perspectives
by: Alberto Zambelli, et al.
Published: (2023-01-01)

In-Silico Identification of Novel Pharmacological Synergisms: The Trabectedin Case
by: Laura Mannarino, et al.
Published: (2024-02-01)

Multifaceted Effects of Kinase Inhibitors on Pancreatic Cancer Cells Reveals Pivotal Entities with Therapeutic Implications
by: Yoo Na Kim, et al.
Published: (2023-06-01)

Future Options of Molecular-Targeted Therapy in Small Cell Lung Cancer
by: Arik Bernard Schulze, et al.
Published: (2019-05-01)

Harnessing DLL3 inhibition: From old promises to new therapeutic horizons
by: Diego Luigi Cortinovis, et al.
Published: (2022-12-01)

Dual PDK1/Aurora Kinase A Inhibitors Reduce Pancreatic Cancer Cell Proliferation and Colony Formation
by: Ilaria Casari, et al.
Published: (2019-10-01)

Thyroid Dysfunction in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors (ICIs): Outcomes in a Multiethnic Urban Cohort
by: Angelica D’Aiello, et al.
Published: (2021-03-01)